Aeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 9,300 shares, a decrease of 46.6% from the May 31st total of 17,400 shares. Based on an average daily volume of 9,100 shares, the short-interest ratio is presently 1.0 days. Approximately 0.3% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Aeterna Zentaris in a research report on Tuesday. They set a “sell” rating for the company.

Aeterna Zentaris Price Performance

AEZS opened at $4.42 on Friday. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.80. The business has a 50 day simple moving average of $7.48 and a two-hundred day simple moving average of $7.70. The firm has a market capitalization of $7.91 million, a price-to-earnings ratio of -0.30 and a beta of 1.60.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share for the quarter. Aeterna Zentaris had a negative return on equity of 83.45% and a negative net margin of 760.32%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.